194 related articles for article (PubMed ID: 37146263)
1. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
Abel GA; Hebert D; Lee C; Rollison D; Gillis N; Komrokji R; Foran JM; Liu JJ; Al Baghdadi T; Deeg J; Gore S; Saber W; Wilson S; Otterstatter M; Thompson J; Borchert C; Padron E; DeZern A; Cella D; Sekeres MA
Blood Adv; 2023 Jul; 7(14):3506-3515. PubMed ID: 37146263
[TBL] [Abstract][Full Text] [Related]
2. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
3. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
Gorak EJ; Otterstatter M; Al Baghdadi T; Gillis N; Foran JM; Liu JJ; Bejar R; Gore SD; Kroft SH; Harrington A; Saber W; Starczynowski D; Rollison DE; Zhang L; Moscinski L; Wilson S; Thompson J; Borchert C; Sherman S; Hebert D; Walker ME; Padron E; DeZern AE; Sekeres MA
Blood Adv; 2023 Oct; 7(20):6120-6129. PubMed ID: 37552083
[TBL] [Abstract][Full Text] [Related]
4. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.
Sekeres MA; Gore SD; Stablein DM; DiFronzo N; Abel GA; DeZern AE; Troy JD; Rollison DE; Thomas JW; Waclawiw MA; Liu JJ; Al Baghdadi T; Walter MJ; Bejar R; Gorak EJ; Starczynowski DT; Foran JM; Cerhan JR; Moscinski LC; Komrokji RS; Deeg HJ; Epling-Burnette PK
Leuk Lymphoma; 2019 Dec; 60(13):3161-3171. PubMed ID: 31111762
[TBL] [Abstract][Full Text] [Related]
5. Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT project.
Efficace F; Koinig K; Cottone F; Bowen D; Mittelman M; Sommer K; Langemeijer S; Culligan D; Filanovsky K; Storck M; Smith A; van Marrewijk C; Dugas M; Stojkov I; Siebert U; de Witte T; Stauder R
Cancer Med; 2023 Mar; 12(6):7529-7539. PubMed ID: 36533415
[TBL] [Abstract][Full Text] [Related]
6. [Significance of Targeted Sequencing Assay for Patients with Suspected Myeloid Malignancies].
Zhang LJ; Shi YY; Chen Y; Deng Y; Ding YH; Li Z; Chen KK; Ding BH; Wang CL; Yu L; He ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1985-1990. PubMed ID: 33283730
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis.
Stauder R; Lambert J; Desruol-Allardin S; Savre I; Gaugler L; Stojkov I; Siebert U; Chevrou-Séverac H
Eur J Haematol; 2020 May; 104(5):476-487. PubMed ID: 31985078
[TBL] [Abstract][Full Text] [Related]
8. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
9. The anemia-independent impact of myelodysplastic syndromes on health-related quality of life.
Wouters HJCM; Conrads-Frank A; Koinig KA; Smith A; Yu G; de Witte T; Wolffenbuttel BHR; Huls G; Siebert U; Stauder R; van der Klauw MM;
Ann Hematol; 2021 Dec; 100(12):2921-2932. PubMed ID: 34476573
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
13. Deep immunophenotypic analysis of the bone marrow progenitor cells in myelodysplastic syndromes.
Shameli A; Dharmani-Khan P; Auer I; Shabani-Rad MT
Leuk Res; 2023 Nov; 134():107401. PubMed ID: 37774446
[TBL] [Abstract][Full Text] [Related]
14. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
15. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
16. LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
Kaastrup K; Gillberg L; Mikkelsen SU; Ørskov AD; Schöllkopf C; Mortensen BK; Porse B; Hansen JW; Grønbæk K
Clin Epigenetics; 2023 May; 15(1):91. PubMed ID: 37237325
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
18. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes.
Jansen AJ; Essink-Bot ML; Beckers EA; Hop WC; Schipperus MR; Van Rhenen DJ
Br J Haematol; 2003 Apr; 121(2):270-4. PubMed ID: 12694248
[TBL] [Abstract][Full Text] [Related]
19. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
20. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
